NCT04485845

Metformin Versus Vildagliptin in Reducing Risk of Metabolic Syndrome Complications Progression

Comparative Effecacy of Metformin and Vildagliptin on Cardiometabolic Risk Factors, Metabolic Syndrome, and Diabetic Nephropathy Progression

• Status: Unknown
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 39 (estimated)
• Sponsor: Cairo University · Academic / Other
• Sex: All
• Age: 40 Years – 70 Years
• Healthy volunteers: Not accepted

Summary

Several crosssectional and prospective studies have shown that metabolic syndrome and its related components are associated with both prevalent and incident CKD . Although the mechanisms for these cardiovascular benefits of Metformin and vildagliptin remain unclear, they extend well beyond glycemic lowering, and therefore are probably best considered diverse "cardiometabolic" pharmaceuticals rather than simply type 2 diabetes drugs. Metformin and vildagliptin have known vasculoprotective actions, but the value of these drugs on drug-naïve diabetic patients during 24 week use warrants investigation. The investigator's purpose was to observe their effects on weight control, Cardiometabolic Risk Factors, Metabolic Syndrome risk, and diabetic nephrooathy Progression.

Detailed description

the current study is investigating the relation betweeneach componant of metabolic syndrome and kidney injury incidence or prevalence, and the mechanism of its occurence. the kidney protective effect of metformin and vildagliptin and the mechanism of this action whether it is related to their glucose lowering mechanism or not is also one of the important points to be investigated in the study

Conditions

• Metabolic Syndrome
• Diabete Type 2
• Kidney Insufficiency

Interventions

Type	Name	Description
DRUG	Vildagliptin	to compare the effect of both metformin and vildagliptin on the progression of diabetes and metabolic complications and risk factors
DRUG	Captopril Tablets	used to treat hypertension in metabolic syndrome patients and as a renal protector
DRUG	MetFORMIN 500 Mg Oral Tablet	antihyperglycemic drug for elevated plasma glucose level and help in weight loss for patients suffering from diabetes or metabolic syndrome

Timeline

• Start date: 2019-11-01
• Primary completion: 2020-08-30
• Completion: 2020-09-30
• First posted: 2020-07-24
• Last updated: 2020-07-24

Locations

1 site across 1 country: Egypt